Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Catalyst Biosciences Inc (CBIO) today and set a price target of $35. The company’s shares closed yesterday at $8.99, close to its 52-week low of $6.20.
Amusa noted:
“We thus continue to “view the phase IIb DalcA [non-GT] study as an arbiter of whether or not a DalcA transgene would have value.” Catalyst is part of the emerging theme of synthetic biology in gene therapy. See our 4 February 2019 research, “Viral News in Genetic Medicines: 2018 in review, and what we expect for 2019″.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.2% and a 47.0% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Logicbio Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Catalyst Biosciences Inc with a $29.50 average price target, implying a 228.1% upside from current levels. In a report issued on January 31, Oppenheimer also reiterated a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37 and a one-year low of $6.20. Currently, Catalyst Biosciences Inc has an average volume of 222.8K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant.
